Es gab 50 kürzliche Insider-Transaktionen für Mereo BioPharma Group plc (MREO), darunter 26 Käufe und 24 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $5.75M und die gesamten Insider-Verkäufe auf $2.67M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Wyzga Michael S, Pakianathan Deepika, Yoskowitz Marc J. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — MREO
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-02-26 |
Wyzga Michael S |
Director |
RSU-Zuteilung |
66,000 |
$0.39 |
$25.74K |
66,000 |
| 2026-02-26 |
Pakianathan Deepika |
Director |
RSU-Zuteilung |
66,000 |
$0.39 |
$25.74K |
66,000 |
| 2026-02-26 |
Yoskowitz Marc J |
Director |
RSU-Zuteilung |
66,000 |
$0.39 |
$25.74K |
66,000 |
| 2026-02-26 |
Jenkins Annalisa |
Director |
RSU-Zuteilung |
66,000 |
$0.39 |
$25.74K |
66,000 |
| 2026-02-26 |
Jacquet Pierre |
Director |
RSU-Zuteilung |
66,000 |
$0.39 |
$25.74K |
66,000 |
| 2026-02-26 |
Bender Jeremy |
Director |
RSU-Zuteilung |
66,000 |
$0.39 |
$25.74K |
66,000 |
| 2026-02-26 |
Shames Daniel |
Director |
RSU-Zuteilung |
66,000 |
$0.39 |
$25.74K |
66,000 |
| 2026-02-26 |
Ekblom Anders |
Director |
RSU-Zuteilung |
66,000 |
$0.39 |
$25.74K |
66,000 |
| 2026-02-01 |
Scots-knight Denise |
Chief Executive Officer |
RSU-Zuteilung |
345,000 |
$1.00 |
$345K |
345,000 |
| 2026-02-01 |
Lewicki John A. |
Chief Scientific Officer |
RSU-Zuteilung |
46,637 |
$1.00 |
$46.64K |
46,637 |
| 2026-02-01 |
Sermon Charles |
General Counsel |
RSU-Zuteilung |
105,250 |
$1.00 |
$105.25K |
105,250 |
| 2026-02-01 |
Fox Christine Ann |
Chief Financial Officer |
RSU-Zuteilung |
105,250 |
$1.00 |
$105.25K |
105,250 |
| 2026-02-01 |
Hughes-wilson Alexandra |
See Remarks |
RSU-Zuteilung |
61,250 |
$1.00 |
$61.25K |
61,250 |
| 2025-02-05 |
Wyzga Michael S |
Director |
RSU-Zuteilung |
30,487 |
- |
- |
30,487 |
| 2025-02-05 |
Pakianathan Deepika |
Director |
RSU-Zuteilung |
55,000 |
$3.16 |
$173.8K |
55,000 |
| 2025-02-05 |
Yoskowitz Marc J |
Director |
RSU-Zuteilung |
13,719 |
- |
- |
13,719 |
| 2025-02-05 |
Jenkins Annalisa |
Director |
RSU-Zuteilung |
15,243 |
- |
- |
15,243 |
| 2025-02-05 |
Jacquet Pierre |
Director |
RSU-Zuteilung |
15,243 |
- |
- |
15,243 |
| 2025-02-05 |
Bender Jeremy |
Director |
RSU-Zuteilung |
16,768 |
- |
- |
16,768 |
| 2025-02-05 |
Shames Daniel |
Director |
RSU-Zuteilung |
13,719 |
- |
- |
13,719 |
| 2025-02-05 |
Ekblom Anders |
Director |
RSU-Zuteilung |
19,054 |
- |
- |
19,054 |
| 2025-01-25 |
Scots-knight Denise |
Chief Executive Officer |
RSU-Zuteilung |
825,000 |
$2.91 |
$2.4M |
825,000 |
| 2025-01-25 |
Lewicki John A. |
Chief Scientific Officer |
RSU-Zuteilung |
116,000 |
$2.91 |
$337.56K |
116,000 |
| 2025-01-25 |
Sermon Charles |
General Counsel |
RSU-Zuteilung |
262,000 |
$2.91 |
$762.42K |
262,000 |
| 2025-01-25 |
Fox Christine Ann |
Chief Financial Officer |
RSU-Zuteilung |
262,000 |
$2.91 |
$762.42K |
262,000 |
| 2025-01-25 |
Hughes-wilson Alexandra |
See Remarks |
RSU-Zuteilung |
154,000 |
$2.91 |
$448.14K |
154,000 |
| 2024-09-13 |
Scots-knight Denise |
Chief Executive Officer |
Informierter Verkauf |
60,046 |
$4.22 |
$253.45K |
808,921 |
| 2024-09-13 |
Lewicki John A. |
Chief Scientific Officer |
Informierter Verkauf |
10,937 |
$4.22 |
$46.17K |
78,630 |
| 2024-09-13 |
Sermon Charles |
General Counsel |
Informierter Verkauf |
20,946 |
$4.22 |
$88.41K |
219,061 |
| 2024-09-13 |
Fox Christine Ann |
Chief Financial Officer |
Informierter Verkauf |
19,158 |
$4.22 |
$80.87K |
89,285 |
| 2024-09-13 |
Hughes-wilson Alexandra |
See Remarks |
Informierter Verkauf |
84,008 |
$4.22 |
$354.6K |
50,475 |
| 2024-09-12 |
Scots-knight Denise |
Chief Executive Officer |
Informierter Verkauf |
28,611 |
$4.47 |
$127.97K |
868,967 |
| 2024-09-12 |
Lewicki John A. |
Chief Scientific Officer |
Informierter Verkauf |
5,212 |
$4.47 |
$23.31K |
89,567 |
| 2024-09-12 |
Sermon Charles |
General Counsel |
Informierter Verkauf |
9,980 |
$4.47 |
$44.64K |
240,007 |
| 2024-09-12 |
Fox Christine Ann |
Chief Financial Officer |
Informierter Verkauf |
9,128 |
$4.47 |
$40.83K |
108,443 |
| 2024-09-12 |
Hughes-wilson Alexandra |
See Remarks |
Informierter Verkauf |
40,029 |
$4.47 |
$179.04K |
150,787 |
| 2024-09-11 |
Scots-knight Denise |
Chief Executive Officer |
Optionsausübung (Verkauf) |
188,060 |
- |
- |
- |
| 2024-09-11 |
Lewicki John A. |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
46,000 |
- |
- |
- |
| 2024-09-11 |
Sermon Charles |
General Counsel |
Optionsausübung (Verkauf) |
65,600 |
- |
- |
- |
| 2024-09-11 |
Fox Christine Ann |
Chief Financial Officer |
Optionsausübung (Verkauf) |
60,000 |
- |
- |
- |
| 2024-09-11 |
Hughes-wilson Alexandra |
See Remarks |
Optionsausübung (Verkauf) |
75,000 |
$1.01 |
$75.75K |
- |
| 2024-08-22 |
Pakianathan Deepika |
Director |
Informierter Verkauf |
105,244 |
$4.43 |
$466.21K |
- |
| 2024-06-26 |
Scots-knight Denise |
Chief Executive Officer |
Informierter Verkauf |
92,273 |
$3.39 |
$313.1K |
709,518 |
| 2024-06-26 |
Lewicki John A. |
Chief Scientific Officer |
Informierter Verkauf |
16,808 |
$3.39 |
$57.03K |
48,779 |
| 2024-06-26 |
Sermon Charles |
General Counsel |
Informierter Verkauf |
32,187 |
$3.39 |
$109.22K |
184,387 |
| 2024-06-26 |
Fox Christine Ann |
Chief Financial Officer |
Informierter Verkauf |
29,439 |
$3.39 |
$99.89K |
57,571 |
| 2024-06-26 |
Hughes-wilson Alexandra |
See Remarks |
Informierter Verkauf |
22,968 |
$3.39 |
$77.94K |
34,548 |
| 2024-06-25 |
Scots-knight Denise |
Chief Executive Officer |
Informierter Verkauf |
40,712 |
$3.69 |
$150.39K |
801,791 |
| 2024-06-25 |
Lewicki John A. |
Chief Scientific Officer |
Informierter Verkauf |
7,416 |
$3.69 |
$27.39K |
65,587 |
| 2024-06-25 |
Sermon Charles |
General Counsel |
Informierter Verkauf |
14,202 |
$3.69 |
$52.46K |
216,574 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
